Assay for distinguishing between sepsis and systemic inflammatory response syndrome

A method of obtaining a biofluid sample from a human test patient having, or suspected of having, sepsis or systemic inflammatory response syndrome (SIRS), and assaying the biofluid sample, for:

• a) an amount of FAM20A and OLAH in said sample;
• and
• b) an amount of one or more biomarker selected from consisting essentially of ITGA7, MMP9, ADM, TDR9, IL10, and CD177 in the sample;
• and
• c) (I) an amount of:
• (i) sepsis biomarker ITGB3, and an amount of two or more additional sepsis biomarkers selected from the group consisting essentially of ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4, or
• (ii) sepsis biomarker CMTM5, and an amount of two or more additional sepsis biomarkers selected from the group consisting essentially of ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, PPBP, and PF4, or
• (iii) sepsis biomarker PF4, and an amount of two or more additional sepsis biomarkers selected from the group consisting essentially of ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5 and PPBP;
• or
• (II) an amount of:
• (i) SIRS biomarker PLA2G7, and an amount of two or more additional SIRS biomarkers selected from the group consisting essentially of ARHGEF10L, MYCL, TGFBI, and GPR124;
• or
• (ii) SIRS biomarker ARHGEF10L, and an amount of two or more additional SIRS biomarkers selected from the group consisting essentially of PLA2G7, MYCL, TGFBI, and GPR124;
• or
• (iii) SIRS biomarker GPR124, and an amount of two or more additional SIRS biomarkers selected from the group consisting essentially of ARHGEF10L, PLA2G7, MYCL, and TGFBI.

A method of treating a systemic inflammatory condition in a human patient, said method comprising:

• (a) obtaining the results of an in vitro method, where said method comprises:
• (i) detecting an amount of biomarkers FAM20A and OLAH in a sample obtained from the human patient, and
• (ii) detecting an amount of one or more biomarker selected from the group consisting essentially of ITGA7, MMP9, ADM, TDR9, IL10, and CD177 in a sample obtained from the human patient;
• (b) comparing the amount of the biomarkers detected in (a) to a corresponding reference value representative of a healthy individual;
• (c) identifying a concentration difference for said biomarkers in the sample relative to the reference standard;
• and
• (d) administering a therapy for a systemic inflammatory condition wherein the concentration difference for each of said biomarkers is an elevated concentration.